Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 9/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8076585 | 1.00 | ADRB3 (0.67) | ADRB3ADRB1GLAADRB2BCHE | |
| SCHEMBL7057571 | 1.00 | ADRB3 (0.67) | ADRB3ADRB1GLAADRB2BCHE | |
| SCHEMBL4071040 | 1.00 | ADRB3 (0.67) | ADRB3ADRB1GLAADRB2BCHE | |
| SCHEMBL13799337 | 1.00 | ADRB3 (0.67) | ADRB3ADRB1GLAADRB2BCHE | |
| SCHEMBL7053502 | 1.00 | ADRB3 (0.67) | ADRB3ADRB1GLAADRB2BCHE | |
| Hydrochloric Acid SCHEMBL7053904 | 0.99 | ADRB3 (0.66) | ADRB3ADRB1GLAADRB2BCHE | |
| Maleic Acid SCHEMBL4071458 | 0.95 | ADRB3 (0.62) | ADRB3ADRB1 | |
| Fumaric Acid SCHEMBL4071460 | 0.95 | ADRB3 (0.62) | ADRB3ADRB1 | |
| SCHEMBL7058076 | 0.93 | ADRB3 (0.68) | ADRB3ADRB1GLAADRB2 | |
| SCHEMBL8073362 | 0.93 | ADRB3 (0.68) | ADRB3ADRB1GLAADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064758-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF DEPRESSION | MEDICINOVA, INC. | 2008-03-13 | — | — | US | claimed |
| EP-0940387-B1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2003-05-07 | — | — | EP | claimed |
| US-6069176-A | PHENYLETHANOLAMINE COMPOUNDS WITH A BETA-3 ADRENERGIC RECEPTOR STIMULATING EFFECT, USE AS A THERAPY FOR URINARY INCONTINENCE | MITSUBISHI-TOKYO PHARMACEUTICALS, INC. (JP) | 2000-05-30 | — | — | US | claimed |
| EP-0940387-A1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | TOKYO TANABE COMPANY LIMITED (JP) | 1999-09-08 | — | — | EP | claimed |
| US-7544841-B2 | Production method of phenylethanolamine compound, and its intermediate | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20080064758-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF DEPRESSION | MEDICINOVA, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064758-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF DEPRESSION | MEDICINOVA, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064758-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF DEPRESSION | MEDICINOVA, INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2008024787-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF DEPRESSION | MEDICINOVA, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070287864-A1 | Production Method of Phenylethanolamine Compound, and Its Intermediate | MITSUBISHI PHARMA CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1806335-A1 | METHOD FOR PRODUCING PHENYLETHANOLAMINE COMPOUND AND INTERMEDIATE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-6069176-A | PHENYLETHANOLAMINE COMPOUNDS WITH A BETA-3 ADRENERGIC RECEPTOR STIMULATING EFFECT, USE AS A THERAPY FOR URINARY INCONTINENCE | MITSUBISHI-TOKYO PHARMACEUTICALS, INC. (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0940387-A1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | TOKYO TANABE COMPANY LIMITED (JP) | 1999-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064758-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF DEPRESSION | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885GLA 2347/4885 |
| US-20070287864-A1 | Production Method of Phenylethanolamine Compound, and Its Intermediate | PNMT, COMT, CYP2E1 | ADRB3 4/4885ADRB1 7/4885GLA 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.